European Institute of Science AB

NGM:EURI B Stock Report

Mkt Cap: kr16.0m

We’ve recently updated our valuation analysis.

European Institute of Science Valuation

Is EURI B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EURI B?

Other financial metrics that can be useful for relative valuation.

EURI B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue22.1x
Enterprise Value/EBITDA-4.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does EURI B's PS Ratio compare to its peers?

The above table shows the PS ratio for EURI B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12.6x
DIABIO Diagonal Bio
5.3xn/akr21.6m
IDOGEN Idogen
3.7x-171.6%kr13.0m
QUIA QuiaPEG Pharmaceuticals Holding
5.1xn/akr28.3m
PROGEN Prostatype Genomics
36.1xn/akr40.2m
EURI B European Institute of Science
30.2xn/akr16.0m

Price-To-Sales vs Peers: EURI B is expensive based on its Price-To-Sales Ratio (30.2x) compared to the peer average (12.6x).


Price to Earnings Ratio vs Industry

How does EURI B's PE Ratio compare vs other companies in the SE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.5%
n/an/an/a

Price-To-Sales vs Industry: EURI B is expensive based on its Price-To-Sales Ratio (30.2x) compared to the Swedish Biotechs industry average (22.5x)


Price to Sales Ratio vs Fair Ratio

What is EURI B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EURI B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate EURI B's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of EURI B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EURI B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EURI B's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies